Summary & Overview
HCPCS J3145: Injection, Testosterone Undecanoate, 1 mg
HCPCS Level II code J3145 represents the injectable medication testosterone undecanoate, 1 mg. As a drug administration code, it matters nationally for outpatient medical billing, hormone therapy management, and payer coverage determinations involving androgen replacement or related therapeutic uses. Accurate coding of this product affects claims processing, medical necessity review, and pharmacy/medical benefit delineation.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides readers with benchmarks for how this HCPCS Level II code is billed across common outpatient sites, summarizes payer coverage considerations, and outlines clinical context for its use as an injectable testosterone therapy. It also highlights relevant policy items that influence reimbursement pathways and claim adjudication.
Readers will learn what the code denotes, where the service is typically provided, which major payers are relevant to billing, and which topics to consult for payer-specific policy language or benefit design. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J3145 denotes Injection, testosterone undecanoate, 1 mg. This code represents a billed administration of the specified testosterone formulation as a medication service. The service type is an injectable hormone therapy medication, typically administered as an intramuscular injection.
The typical site of service for billing with this code is outpatient clinical settings where parenteral medications are administered, including physician offices, outpatient clinics, and ambulatory infusion or injection suites.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult male with hypogonadism presenting for testosterone replacement therapy. The clinician documents symptoms (low libido, fatigue, decreased muscle mass) and confirms low serum testosterone on morning labs. After counseling, the patient receives an intramuscular injection of testosterone undecanoate, dosed per product labeling; J3145 represents the administered drug billed per milligram. The clinical workflow: evaluation and informed consent during an office visit; baseline labs (total testosterone, hematocrit, PSA as clinically indicated); administration of the intramuscular injection in an outpatient clinic or physician office by a qualified clinician (endocrinologist, urologist, or primary care physician); monitoring for adverse reactions for a brief period post-injection; documentation of drug lot, quantity, route, and site; scheduled follow-up visits and periodic laboratory monitoring per standard clinical practice.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no special circumstances apply |
11 | Primary procedure |